Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 17,818 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Dose level 3 Clear all

Conditions: Soft Tissue Sarcoma
Interventions: Hypofractionated Radiotherapy; Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pre-Exposure Prophylaxis
Interventions: Probenecid Oral Tablet, Tenofovir disoproxil fumarate/Emtricitabine; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Opiod Use Disorder
Interventions: ANS-6637; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions: vorinostat, conventional surgery; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Gastro-Intestinal Cancer
Interventions: 5-FU, Leucovorin, Irinotecan, Brivanib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Los Angeles, California • Dallas, Texas • Temple, Texas

Conditions: Obesity, Overweight, Weight Maintenance
Interventions: VRB-101, Placebo; Drug
Lead sponsor: Verdiva Bio Dev Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 20
States / cities: Cullman, Alabama • Phoenix, Arizona • Tempe, Arizona + 16 more

Conditions: Schizotypal Personality Disorder, SPD
Interventions: Cognitive Remediation Therapy, Guanfacine, Placebo; Behavioral · Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
Interventions: galinpepimut-S, pembrolizumab, Montanide, GM-CSF; Biological · Other
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 12
States / cities: Santa Rosa, California • Whittier, California • Miami, Florida + 9 more

Conditions: Schizophrenia
Interventions: AMG 747, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 18
States / cities: Anaheim, California • Cerritos, California • Culver City, California + 15 more

Conditions: Graft vs. Host Disease
Interventions: Obinutuzumab, Placebo; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 5
States / cities: Palo Alto, California • Boston, Massachusetts • Minneapolis, Minnesota + 1 more

Conditions: Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
Interventions: VX-01, Placebo; Drug
Lead sponsor: Vantage Biosciences Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Beverly Hills, California • Palo Alto, California • Santa Barbara, California + 6 more

Conditions: Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1, Von Willebrand Disease (VWD), Type 2, Von Willebrand Disease (VWD), Type 3
Interventions: HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US); Drug
Lead sponsor: Hemab ApS; Industry
Eligibility: 16 Years to 69 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more

Conditions: Malaria
Interventions: Chloroquine Phosphate, Pyrimethamine, Sanaria PfSPZ Challenge; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bronchitis, Sinusitis, Urinary Tract Infections
Interventions: Fluoroquinolone (FQ), Azithromycin (AZ), Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 239,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Non-alcoholic Steatohepatitis, Hypertriglyceridemia, Non-alcoholic Fatty Liver Disease, Hypercholesterolemia
Interventions: MN-001; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Coronado, California • La Jolla, California • Seattle, Washington

Conditions: Angelman Syndrome
Interventions: ION582; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 0 Years to 50 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 6
States / cities: San Diego, California • Aurora, Colorado • Chicago, Illinois + 3 more

Conditions: Fibrosis
Interventions: BMS-986263, Placebo, Diphenhydramine, Famotidine; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Cypress, California

Conditions: Cancer
Interventions: ALB 109564(a) (12´-methylthiovinblastine dihydrochloride); Drug
Lead sponsor: Albany Molecular Research, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Boston, Massachusetts • The Bronx, New York

Conditions: Schizophrenia
Interventions: Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg, Haloperidol 10mg, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 34
States / cities: Birmingham, Alabama • Cerritos, California • Garden Grove, California + 26 more

Conditions: Cognitive Function, Gaming Performance
Interventions: Placebo, Phosphatidylserine (100 mg), Phosphatidylserine (200 mg); Dietary Supplement
Lead sponsor: Lindenwood University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Hepatitis B
Interventions: Entecavir; Drug
Lead sponsor: Pacific Health Foundation; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 6
States / cities: Palo Alto, California • San Jose, California • Chicago, Illinois + 2 more

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 44
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 37 more

Conditions: Dermatomyositis, Polymyositis
Interventions: tocilizumab, placebo; Drug
Lead sponsor: Chester Oddis; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 7
States / cities: Los Angeles, California • Kansas City, Kansas • Rochester, Minnesota + 4 more

Search by objective public record fields.

Hypofractionated Radiotherapy for Soft Tissue Sarcomas

Assessment of a New "Boosting" Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers

The Influence of ANS-6637 on Midazolam Pharmacokinetics in Healthy Volunteers

Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer

Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

CRT-Guanfacine for SPD

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms

Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

Dose Escalation PfSPZ-CVac

Fluoroquinolone Associated Disability

Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects

HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants

A Trial of ALB 109564(a) in Subjects With Advanced Solid Tumors

A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia

Dose-Response Effect of Phosphatidylserine on eSport Performance

Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders

Ocrelizumab Access by Socio-Economic Status

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis